What Studies Say About BPC-157: A Research Summary
This post highlights published preclinical findings in a research context. For laboratory use only.
BPC-157 (Body Protection Compound-157) has been examined in preclinical models for roles in tissue research, angiogenesis, and cellular responses.
Findings are encouraging for further laboratory exploration; however, they remain non-clinical and should be interpreted within experimental settings.
Key Directions Reported in Preclinical Studies
Mechanistic Notes (In-Vitro)
In tendon fibroblast models, investigators have described upregulation of growth hormone receptor (GHR) expression and increased proliferation markers under specific in-vitro conditions. These findings motivate additional controlled research to clarify pathway engagement and boundaries.
| Focus | Model | Observation |
|---|---|---|
| GHR expression | Tendon fibroblasts (in vitro) | Reported dose/time-dependent upregulation (mRNA & protein). |
| Proliferation markers | Fibroblasts + exogenous GH | Enhanced proliferation signals (e.g., PCNA) in specific conditions. |
Explore BPC-157 for Research
Each batch is independently tested with COAs published for transparency. View current BPC-157 options below:
Research Considerations
- Preclinical scope: Data derive from animal and cell models—non-clinical and exploratory.
- Model variables: Outcomes depend on species, dose, route, and study design.
- Transparency: Review full methods, raw data where available, and batch COAs for materials.
Sources
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157.
Regul Toxicol Pharmacol. 2020;114:104665.
PubMed - Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC-157 enhances the growth hormone receptor expression in tendon fibroblasts.
Molecules. 2014;19(11):19066–19077.
PMC - He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs.
Front Pharmacol. 2022;13:1026182.
PMC